{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:44Z","timestamp":1791983504536,"version":"4.4.0"},"reference-count":177,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Tickle Family Land"},{"name":"Endowed Chair Fund"},{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022750","name":"Office of the Vice President for Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ovarian cancer (OC) represents a collection of rare but lethal gynecologic cancers where the difficulty of early detection due to an often-subtle range of abdominal symptoms contributes to high fatality rates. With the exception of BRCA1\/2 mutation carriers, OC most often manifests as a post-menopausal disease, a time in which the ovaries regress and circulating reproductive hormones diminish. Progesterone is thought to be a \u201cprotective\u201d hormone that counters the proliferative actions of estrogen, as can be observed in the uterus or breast. Like other steroid hormone receptor family members, the transcriptional activity of the nuclear progesterone receptor (nPR) may be ligand dependent or independent and is fully integrated with other ubiquitous cell signaling pathways often altered in cancers. Emerging evidence in OC models challenges the singular protective role of progesterone\/nPR. Herein, we integrate the historical perspective of progesterone on OC development and progression with exciting new research findings and critical interpretations to help paint a broader picture of the role of progesterone and nPR signaling in OC. We hope to alleviate some of the controversy around the role of progesterone and give insight into the importance of nPR actions in disease progression. A new perspective on the role of progesterone and nPR signaling integration will raise awareness to the complexity of nPRs and nPR-driven gene regulation in OC, help to reveal novel biomarkers, and lend critical knowledge for the development of better therapeutic strategies.<\/jats:p>","DOI":"10.1210\/endrev\/bnad018","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T17:57:00Z","timestamp":1685642220000},"page":"1029-1046","source":"Crossref","is-referenced-by-count":17,"title":["Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?"],"prefix":"10.1210","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-8299","authenticated-orcid":false,"given":"Laura J","family":"Mauro","sequence":"first","affiliation":[{"name":"Department of Animal Science-Physiology, University of Minnesota , Saint Paul, MN 55108 , USA"},{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Spartz","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R","family":"Austin","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-3976","authenticated-orcid":false,"given":"Carol A","family":"Lange","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 , USA"},{"name":"Departments of Medicine (Division of Hematology, Oncology & Transplantation) and Pharmacology, University of Minnesota , Minneapolis, MN 55455 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"3","key":"2024042614111135000_bnad018-B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2024042614111135000_bnad018-B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-019-0816-0","article-title":"Novel approaches to ovarian cancer screening","volume":"21","author":"Nebgen","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2024042614111135000_bnad018-B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2024042614111135000_bnad018-B4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2019.12.011","article-title":"Predictors of survival trajectories among women with epithelial ovarian cancer","volume":"156","author":"Peres","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2024042614111135000_bnad018-B5","volume-title":"SEER Cancer Statistics Review, 1975\u20132018","author":"Howlader","year":"2021"},{"issue":"18","key":"2024042614111135000_bnad018-B6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2024042614111135000_bnad018-B7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2024042614111135000_bnad018-B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"J Pathol"},{"issue":"7","key":"2024042614111135000_bnad018-B9","doi-asserted-by":"publisher","first-page":"e207566","DOI":"10.1001\/jamanetworkopen.2020.7566","article-title":"Detection of TP53 clonal variants in papanicolaou test samples collected up to 6 years prior to high-grade serous epithelial ovarian cancer diagnosis","volume":"3","author":"Paracchini","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"2024042614111135000_bnad018-B10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024042614111135000_bnad018-B11","doi-asserted-by":"crossref","first-page":"T49","DOI":"10.1530\/JME-20-0104","article-title":"90 years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future","volume":"65","author":"Horwitz","year":"2020","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2024042614111135000_bnad018-B12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr Rev"},{"issue":"1","key":"2024042614111135000_bnad018-B13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc.2016.113","article-title":"The disparate origins of ovarian cancers: pathogenesis and prevention strategies","volume":"17","author":"Karnezis","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2024042614111135000_bnad018-B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2024042614111135000_bnad018-B15","doi-asserted-by":"publisher","first-page":"668151","DOI":"10.3389\/fonc.2021.668151","article-title":"A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"2024042614111135000_bnad018-B16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s11912-022-01315-y","article-title":"Advancements in low-grade serous carcinoma of the ovary and peritoneum","volume":"24","author":"Grisham","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 1","key":"2024042614111135000_bnad018-B17","doi-asserted-by":"publisher","first-page":"i53","DOI":"10.1093\/annonc\/mdw087","article-title":"Mucinous epithelial ovarian carcinoma","volume":"27","author":"Perren","year":"2016","journal-title":"Ann Oncol"},{"key":"2024042614111135000_bnad018-B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"issue":"2","key":"2024042614111135000_bnad018-B19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/edrv.22.2.0422","article-title":"Ovarian surface epithelium: biology, endocrinology, and pathology","volume":"22","author":"Auersperg","year":"2001","journal-title":"Endocr Rev"},{"issue":"8","key":"2024042614111135000_bnad018-B20","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/en.2007-0030","article-title":"Ovarian epithelial inclusion cysts in chronically superovulated CD1 and Smad2 dominant-negative mice","volume":"148","author":"Burdette","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"2024042614111135000_bnad018-B21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2006.08.052","article-title":"Emerging roles for PAX8 in ovarian cancer and endosalpingeal development","volume":"104","author":"Bowen","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2024042614111135000_bnad018-B22","first-page":"292","article-title":"Incessant ovulation and ovarian cancer\u2014a hypothesis re-visited","volume":"5","author":"Fathalla","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"issue":"9574","key":"2024042614111135000_bnad018-B23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"2024042614111135000_bnad018-B24","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8932","key":"2024042614111135000_bnad018-B25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/s0140-6736(94)90749-8","article-title":"Parity, age at first childbirth, and risk of ovarian cancer","volume":"344","author":"Adami","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"2024042614111135000_bnad018-B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/03014469800005432","article-title":"Pregnancy and menstrual hormone levels in mothers of twins compared to mothers of singletons","volume":"25","author":"Thomas","year":"1998","journal-title":"Ann Hum Biol"},{"issue":"4","key":"2024042614111135000_bnad018-B27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"issue":"25","key":"2024042614111135000_bnad018-B28","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024042614111135000_bnad018-B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.pgp.0000101082.35393.84","article-title":"Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers","volume":"23","author":"Carcangiu","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"2024042614111135000_bnad018-B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/aogs.12516","article-title":"Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study","volume":"94","author":"Madsen","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"2024042614111135000_bnad018-B31","doi-asserted-by":"crossref","first-page":"dju410","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2024042614111135000_bnad018-B32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","article-title":"Pathologic findings in prophylactic oophorectomy specimens in high-risk women","volume":"87","author":"Leeper","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"Suppl 10","key":"2024042614111135000_bnad018-B33","doi-asserted-by":"publisher","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann Oncol"},{"issue":"13","key":"2024042614111135000_bnad018-B34","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-07-4959","article-title":"Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma","volume":"14","author":"Tone","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024042614111135000_bnad018-B35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/cancers13030468","article-title":"Ovulatory follicular fluid facilitates the full transformation process for the development of high-grade serous carcinoma","volume":"13","author":"Hsu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024042614111135000_bnad018-B36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ebiom.2019.01.061","article-title":"IGF-axis confers transformation and regeneration of fallopian tube fimbria epithelium upon ovulation","volume":"41","author":"Hsu","year":"2019","journal-title":"EBioMedicine"},{"key":"2024042614111135000_bnad018-B37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2020.02.017","article-title":"Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: mechanisms and therapeutic implications","volume":"476","author":"Bergsten","year":"2020","journal-title":"Cancer Lett"},{"issue":"10","key":"2024042614111135000_bnad018-B38","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1021\/acscentsci.8b00405","article-title":"Imaging mass spectrometry reveals crosstalk between the fallopian tube and the ovary that drives primary metastasis of ovarian cancer","volume":"4","author":"Zink","year":"2018","journal-title":"ACS Cent Sci"},{"key":"2024042614111135000_bnad018-B39","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/S0090-8258(22)01470-6","article-title":"Norepinephrine promotes anoikis resistance in fallopian tube secretory cells through beta adrenergic signaling","volume":"166","author":"Gysler","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2024042614111135000_bnad018-B40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/path.2739","article-title":"Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube","volume":"222","author":"Chen","year":"2010","journal-title":"J Pathol"},{"issue":"3","key":"2024042614111135000_bnad018-B41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/modpathol.2011.17.5","article-title":"PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer","volume":"25","author":"Quick","year":"2012","journal-title":"Mod Pathol"},{"issue":"5","key":"2024042614111135000_bnad018-B42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/carcin\/bgz127","article-title":"Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling","volume":"41","author":"Colina","year":"2020","journal-title":"Carcinogenesis"},{"issue":"1","key":"2024042614111135000_bnad018-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"2024042614111135000_bnad018-B44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/cancers10080262","article-title":"UnPAXing the divergent roles of PAX2 and PAX8 in high-grade serous ovarian cancer","volume":"10","author":"Hardy","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024042614111135000_bnad018-B45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study","volume":"35","author":"Vang","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"2024042614111135000_bnad018-B46","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/JME-14-0252","article-title":"Progesterone action in breast, uterine, and ovarian cancers","volume":"54","author":"Diep","year":"2015","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"2024042614111135000_bnad018-B47","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endrev\/bnab041","article-title":"Membrane-initiated estrogen, androgen, and progesterone receptor signaling in health and disease","volume":"43","author":"Mauvais-Jarvis","year":"2022","journal-title":"Endocr Rev"},{"issue":"11","key":"2024042614111135000_bnad018-B48","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells11111785","article-title":"Membrane progesterone receptors (mPRs, PAQRs): review of structural and signaling characteristics","volume":"11","author":"Thomas","year":"2022","journal-title":"Cells"},{"issue":"7","key":"2024042614111135000_bnad018-B49","doi-asserted-by":"crossref","first-page":"bqac078","DOI":"10.1210\/endocr\/bqac078","article-title":"Pleiotropic actions of PGRMC proteins in cancer","volume":"163","author":"Pru","year":"2022","journal-title":"Endocrinology"},{"issue":"2","key":"2024042614111135000_bnad018-B50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mce.2011.07.017","article-title":"Structural and functional analysis of domains of the progesterone receptor","volume":"348","author":"Hill","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"19","key":"2024042614111135000_bnad018-B51","doi-asserted-by":"crossref","first-page":"8926","DOI":"10.1093\/nar\/gkt706","article-title":"A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells","volume":"41","author":"Hagan","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2024042614111135000_bnad018-B52","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/MCB.01246-10","article-title":"ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells","volume":"31","author":"Hagan","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2024042614111135000_bnad018-B53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1210\/me.2006-0337","article-title":"The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle","volume":"21","author":"Boonyaratanakornkit","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2024042614111135000_bnad018-B54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/me.2006-0041","article-title":"Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity","volume":"21","author":"Arnett-Mansfield","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"10","key":"2024042614111135000_bnad018-B55","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1101\/gad.215293.113","article-title":"Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes","volume":"27","author":"Vicent","year":"2013","journal-title":"Genes Dev"},{"issue":"3","key":"2024042614111135000_bnad018-B56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/b:jomg.0000010028.48159.84","article-title":"Expression profiling of human breast cancers and gene regulation by progesterone receptors","volume":"8","author":"Jacobsen","year":"2003","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"2024042614111135000_bnad018-B57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/1541-7786.MCR-15-0431","article-title":"Active FOXO1 is a key determinant of isoform-specific progesterone receptor transactivation and senescence programming","volume":"14","author":"Diep","year":"2016","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2024042614111135000_bnad018-B58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-017-0462-7","article-title":"Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs","volume":"10","author":"Knutson","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2024042614111135000_bnad018-B59","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/clinem\/dgab195","article-title":"Progesterone receptors promote quiescence and ovarian cancer cell phenotypes via DREAM in p53-mutant fallopian tube models","volume":"106","author":"Mauro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024042614111135000_bnad018-B60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsbmb.2013.12.008","article-title":"Post-translational modifications of the progesterone receptors","volume":"140","author":"Abdel-Hafiz","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2024042614111135000_bnad018-B61","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1128\/MCB.01539-06","article-title":"Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1\/2 mitogen-activated protein kinase in breast cancer cells","volume":"27","author":"Faivre","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2024042614111135000_bnad018-B62","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.0436133100","article-title":"Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2024042614111135000_bnad018-B63","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1073\/pnas.0336132100","article-title":"Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2024042614111135000_bnad018-B64","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.steroids.2008.05.003","article-title":"Heterologous expression of human mPR\u03b1, mPR\u03b2 and mPR\u03b3 in yeast confirms their ability to function as membrane progesterone receptors","volume":"73","author":"Smith","year":"2008","journal-title":"Steroids"},{"issue":"3","key":"2024042614111135000_bnad018-B65","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.repbio.2021.100529","article-title":"PAQR7: an intermediary mediating nongenomic progesterone action in female reproductive tissue","volume":"21","author":"Wang","year":"2021","journal-title":"Reprod Biol"},{"issue":"7","key":"2024042614111135000_bnad018-B66","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/me.2005-0243","article-title":"Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term","volume":"20","author":"Karteris","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2024042614111135000_bnad018-B67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1042\/BST20110638","article-title":"Non-genomic progesterone signalling and its non-canonical receptor","volume":"40","author":"Moussatche","year":"2012","journal-title":"Biochem Soc Trans"},{"issue":"1-2","key":"2024042614111135000_bnad018-B68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.steroids.2010.09.006","article-title":"Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications","volume":"76","author":"Dressing","year":"2011","journal-title":"Steroids"},{"issue":"4","key":"2024042614111135000_bnad018-B69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12672-010-0023-9","article-title":"Expression of membrane progesterone receptors (mPR\/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events","volume":"1","author":"Charles","year":"2010","journal-title":"Horm Cancer"},{"issue":"3","key":"2024042614111135000_bnad018-B70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1432-1033.1996.0726u.x","article-title":"Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes","volume":"239","author":"Meyer","year":"1996","journal-title":"Eur J Biochem"},{"issue":"3","key":"2024042614111135000_bnad018-B71","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/en.2013-1991","article-title":"Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPR\u03b1) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors","volume":"155","author":"Thomas","year":"2014","journal-title":"Endocrinology"},{"issue":"8","key":"2024042614111135000_bnad018-B72","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1021\/bi501177e","article-title":"Spectroscopic and mutagenesis studies of human PGRMC1","volume":"54","author":"Kaluka","year":"2015","journal-title":"Biochemistry"},{"issue":"2","key":"2024042614111135000_bnad018-B73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bbcan.2016.07.004","article-title":"The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology","volume":"1866","author":"Cahill","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"2024042614111135000_bnad018-B74","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.3390\/cancers13235953","article-title":"Progesterone receptor membrane component (PGRMC)1 and PGRMC2 and their roles in ovarian and endometrial cancer","volume":"13","author":"Peluso","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024042614111135000_bnad018-B75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0002-9378(66)90462-5","article-title":"Steroid synthesis in cystadenocarcinoma of the ovaries","volume":"94","author":"Plotz","year":"1966","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2024042614111135000_bnad018-B76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0002-9378(67)90318-3","article-title":"Enzymatic activities related to steroidogenesis in postmenopausal ovaries of patients with and without endometrial carcinoma","volume":"99","author":"Plotz","year":"1967","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2024042614111135000_bnad018-B77","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0378-5122(88)90098-9","article-title":"Hormonal activity of epithelial ovarian tumours in post-menopausal women","volume":"9","author":"Heinonen","year":"1988","journal-title":"Maturitas"},{"issue":"5","key":"2024042614111135000_bnad018-B78","first-page":"889","article-title":"Correlation of aromatase activity and steroid receptors in human ovarian carcinoma","volume":"6","author":"Kuhnel","year":"1986","journal-title":"Anticancer Res"},{"issue":"5","key":"2024042614111135000_bnad018-B79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.2910320508","article-title":"Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas","volume":"32","author":"Jones","year":"1983","journal-title":"Int J Cancer"},{"issue":"3","key":"2024042614111135000_bnad018-B80","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0022-4731(82)90056-5","article-title":"Estradiol and progesterone binding components in the cytosol of normal human fallopian tubes","volume":"16","author":"Pollow","year":"1982","journal-title":"J Steroid Biochem"},{"issue":"5","key":"2024042614111135000_bnad018-B81","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ijc.2910310512","article-title":"3H-estradiol and 3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue","volume":"31","author":"Pollow","year":"1983","journal-title":"Int J Cancer"},{"issue":"2","key":"2024042614111135000_bnad018-B82","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/0090-8258(86)90221-0","article-title":"Estrogen and progesterone receptors in epithelial ovarian malignancies","volume":"23","author":"Sutton","year":"1986","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2024042614111135000_bnad018-B83","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1349-7006.2005.00040.x","article-title":"StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies","volume":"96","author":"Abd-Elaziz","year":"2005","journal-title":"Cancer Sci"},{"issue":"4","key":"2024042614111135000_bnad018-B84","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/modpathol.2016.219","article-title":"Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis","volume":"30","author":"Blanco","year":"2017","journal-title":"Mod Pathol"},{"issue":"3","key":"2024042614111135000_bnad018-B85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00004347-199807000-00011","article-title":"Histopathologic and immunohistochemical study of steroidogenic cells in the stroma of ovarian tumors","volume":"17","author":"Ishikura","year":"1998","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"2024042614111135000_bnad018-B86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1440-1827.2007.02099.x","article-title":"Ovarian epithelial carcinoma with estrogen-producing stroma","volume":"57","author":"Tokunaga","year":"2007","journal-title":"Pathol Int"},{"issue":"2","key":"2024042614111135000_bnad018-B87","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1073\/pnas.67.2.501","article-title":"Progesterone \u201creceptors\u201d in the cytoplasm and nucleus of chick oviduct target tissue","volume":"67","author":"O\u2019Malley","year":"1970","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024042614111135000_bnad018-B88","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1073\/pnas.64.1.148","article-title":"Purification of an estrophilic protein from calf uterus","volume":"64","author":"De Sombre","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2024042614111135000_bnad018-B89","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1021\/bi00393a045","article-title":"Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies","volume":"26","author":"Estes","year":"1987","journal-title":"Biochemistry"},{"issue":"9","key":"2024042614111135000_bnad018-B90","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1073\/pnas.74.9.3681","article-title":"Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species","volume":"74","author":"Greene","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2024042614111135000_bnad018-B91","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.5858\/arpa.2016-0497-OA","article-title":"Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data","volume":"141","author":"Troxell","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2024042614111135000_bnad018-B92","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"EMBO J"},{"issue":"23","key":"2024042614111135000_bnad018-B93","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1073\/pnas.82.23.7889","article-title":"Cloning of the human estrogen receptor cDNA","volume":"82","author":"Walter","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024042614111135000_bnad018-B94","doi-asserted-by":"publisher","first-page":"16922","DOI":"10.1038\/s41598-017-17265-6","article-title":"The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"2024042614111135000_bnad018-B95","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4161\/cc.24550","article-title":"Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells","volume":"12","author":"Diep","year":"2013","journal-title":"Cell Cycle"},{"issue":"5","key":"2024042614111135000_bnad018-B96","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tranon.2015.09.002","article-title":"Sex steroid hormone receptor expression affects ovarian cancer survival","volume":"8","author":"J\u00f6nsson","year":"2015","journal-title":"Transl Oncol"},{"issue":"3","key":"2024042614111135000_bnad018-B97","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2016.09.024","article-title":"The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status","volume":"143","author":"Shafrir","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2024042614111135000_bnad018-B98","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/j.1365-2559.2011.04028.x","article-title":"Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue","volume":"59","author":"Sinn","year":"2011","journal-title":"Histopathology"},{"issue":"4","key":"2024042614111135000_bnad018-B99","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/IGC.0b013e3181a44b62","article-title":"Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study","volume":"19","author":"Tangjitgamol","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2024042614111135000_bnad018-B100","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2024042614111135000_bnad018-B101","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The origin of ovarian cancer species and precancerous landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am J Pathol"},{"issue":"5","key":"2024042614111135000_bnad018-B102","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/PGP.0000000000000179","article-title":"Immunophenotypic analysis in early Mullerian serous carcinogenesis","volume":"34","author":"Nafisi","year":"2015","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"2024042614111135000_bnad018-B103","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024042614111135000_bnad018-B104","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1054\/bjoc.2000.1463","article-title":"Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies","volume":"83","author":"Akahira","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"2024042614111135000_bnad018-B105","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1349-7006.2002.tb01323.x","article-title":"Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors","volume":"93","author":"Akahira","year":"2002","journal-title":"JPN J Cancer Res"},{"issue":"1","key":"2024042614111135000_bnad018-B106","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/1471-2407-12-553","article-title":"Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival","volume":"12","author":"Lenhard","year":"2012","journal-title":"BMC Cancer"},{"issue":"12","key":"2024042614111135000_bnad018-B107","doi-asserted-by":"publisher","first-page":"R605","DOI":"10.1530\/ERC-18-0179","article-title":"Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer","volume":"25","author":"Lamb","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2024042614111135000_bnad018-B108","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1158\/1078-0432.ccr-03-0141","article-title":"Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates","volume":"10","author":"Hopp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024042614111135000_bnad018-B109","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1210\/en.2018-00990","article-title":"Phosphorylated progesterone receptor isoforms mediate opposing stem cell and proliferative breast cancer cell fates","volume":"160","author":"Truong","year":"2018","journal-title":"Endocrinology"},{"issue":"7","key":"2024042614111135000_bnad018-B110","doi-asserted-by":"publisher","first-page":"djw317","DOI":"10.1093\/jnci\/djw317","article-title":"Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness","volume":"109","author":"Rojas","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024042614111135000_bnad018-B111","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1210\/edrv.18.4.0308","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Graham","year":"1997","journal-title":"Endocr Rev"},{"key":"2024042614111135000_bnad018-B112","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.jsbmb.2020.105599","article-title":"Systemic distribution of progesterone receptor subtypes in human tissues","volume":"199","author":"Asavasupreechar","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"2024042614111135000_bnad018-B113","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.humpath.2007.11.007","article-title":"Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors","volume":"39","author":"Romero-Sanchez","year":"2008","journal-title":"Hum Pathol"},{"issue":"5","key":"2024042614111135000_bnad018-B114","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1210\/jc.2007-2771","article-title":"Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1","volume":"93","author":"Peluso","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024042614111135000_bnad018-B115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4236\/alc.2015.43006","article-title":"PGRMC1 elevation in multiple cancers and essential role in stem cell survival","volume":"4","author":"Hampton","year":"2015","journal-title":"Adv Lung Cancer (Irvine)"},{"issue":"11","key":"2024042614111135000_bnad018-B116","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1210\/en.2009-0730","article-title":"Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice","volume":"150","author":"Peluso","year":"2009","journal-title":"Endocrinology"},{"issue":"2","key":"2024042614111135000_bnad018-B117","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bjc.1962.24","article-title":"Progesterone in the treatment of advanced malignant tumours of breast, ovary and uterus","volume":"16","author":"Jolles","year":"1962","journal-title":"Br J Cancer"},{"issue":"1","key":"2024042614111135000_bnad018-B118","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/edrv-12-1-14","article-title":"Endocrine factors in common epithelial ovarian cancer","volume":"12","author":"Rao","year":"1991","journal-title":"Endocr Rev"},{"issue":"3","key":"2024042614111135000_bnad018-B119","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0090-8258(81)90131-1","article-title":"High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy","volume":"12","author":"Mangioni","year":"1981","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2024042614111135000_bnad018-B120","first-page":"369","article-title":"Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study","volume":"70","author":"Freedman","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"2024042614111135000_bnad018-B121","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0090-8258(87)90208-3","article-title":"Randomized trial of megestrol acetate vs. megestrol acetate\/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma","volume":"28","author":"Belinson","year":"1987","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2024042614111135000_bnad018-B122","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0022-4731(87)91292-1","article-title":"Chemohormonal therapy in advanced ovarian carcinoma","volume":"28","author":"Jeppson","year":"1987","journal-title":"J Steroid Biochem"},{"issue":"10","key":"2024042614111135000_bnad018-B123","doi-asserted-by":"publisher","first-page":"e0204973","DOI":"10.1371\/journal.pone.0204973","article-title":"Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers","volume":"13","author":"Cottu","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 16","key":"2024042614111135000_bnad018-B124","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1200\/JCO.2022.40.16_suppl.5521","article-title":"Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)","volume":"40","author":"Grisham","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024042614111135000_bnad018-B125","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/0277-5379(89)90378-7","article-title":"The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer","volume":"25","author":"van Leeuwen","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"2024042614111135000_bnad018-B126","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ygyno.2022.04.001","article-title":"Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis","volume":"165","author":"Fu","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2024042614111135000_bnad018-B127","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1530\/ERC-14-0282","article-title":"Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer","volume":"21","author":"Schock","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2024042614111135000_bnad018-B128","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/joim.12747","article-title":"The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence","volume":"283","author":"Troisi","year":"2018","journal-title":"J Intern Med"},{"issue":"5","key":"2024042614111135000_bnad018-B129","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/aje\/kwp185","article-title":"Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics","volume":"170","author":"Jordan","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2024042614111135000_bnad018-B130","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31063","article-title":"Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study","volume":"142","author":"Gaitskell","year":"2018","journal-title":"Int J Cancer"},{"issue":"6","key":"2024042614111135000_bnad018-B131","doi-asserted-by":"publisher","first-page":"e200421","DOI":"10.1001\/jamaoncol.2020.0421","article-title":"Association between breastfeeding and ovarian cancer risk","volume":"6","author":"Babic","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024042614111135000_bnad018-B132","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/B978-0-323-68013-4.00003-1","volume-title":"Breastfeeding","author":"Lawrence","year":"2022"},{"issue":"8","key":"2024042614111135000_bnad018-B133","doi-asserted-by":"publisher","first-page":"e0255701","DOI":"10.1371\/journal.pone.0255701","article-title":"Connections between prolactin and ovarian cancer","volume":"16","author":"Alkharusi","year":"2021","journal-title":"PLoS One"},{"issue":"12","key":"2024042614111135000_bnad018-B134","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-08-4652","article-title":"Biological significance of prolactin in gynecologic cancers","volume":"69","author":"Levina","year":"2009","journal-title":"Cancer Res"},{"key":"2024042614111135000_bnad018-B135","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s0065-230x(08)60801-5","article-title":"On the epidemiology of oral contraceptives and disease","volume":"49","author":"Prentice","year":"1987","journal-title":"Adv Cancer Res"},{"key":"2024042614111135000_bnad018-B136","doi-asserted-by":"publisher","first-page":"k3609","DOI":"10.1136\/bmj.k3609","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"2024042614111135000_bnad018-B137","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10552-017-0876-0","article-title":"A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964","volume":"28","author":"Shafrir","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"1","key":"2024042614111135000_bnad018-B138","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.33531","article-title":"Intrauterine device use and risk of ovarian cancer: results from the New England case-control study and nurses\u2019 health studies","volume":"149","author":"Yang","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"2024042614111135000_bnad018-B139","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13053-022-00227-z","article-title":"Beyond the pill: contraception and the prevention of hereditary ovarian cancer","volume":"20","author":"Xia","year":"2022","journal-title":"Hered Cancer Clin Pract"},{"issue":"23","key":"2024042614111135000_bnad018-B140","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","article-title":"Increased risk of endometrial carcinoma among users of conjugated estrogens","volume":"293","author":"Ziel","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"2024042614111135000_bnad018-B141","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"2024042614111135000_bnad018-B142","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jama.288.3.334","article-title":"Menopausal hormone replacement therapy and risk of ovarian cancer","volume":"288","author":"Lacey","year":"2002","journal-title":"JAMA"},{"key":"2024042614111135000_bnad018-B143","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fendo.2019.00801","article-title":"Menopausal hormone replacement therapy and the risk of ovarian cancer: a meta-analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"44","key":"2024042614111135000_bnad018-B144","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024042614111135000_bnad018-B145","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2024042614111135000_bnad018-B146","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10552-012-0127-3","article-title":"Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?","volume":"24","author":"Kim","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"12","key":"2024042614111135000_bnad018-B147","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Widschwendter","year":"2013","journal-title":"Lancet Oncol"},{"issue":"29","key":"2024042614111135000_bnad018-B148","doi-asserted-by":"publisher","first-page":"45317","DOI":"10.18632\/oncotarget.9638","article-title":"Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations","volume":"7","author":"Communal","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2024042614111135000_bnad018-B149","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13058-019-1214-0","article-title":"BRCA1 mutation influences progesterone response in human benign mammary organoids","volume":"21","author":"Davaadelger","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2024042614111135000_bnad018-B150","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/me.2004-0488","article-title":"The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells","volume":"20","author":"Ma","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2024042614111135000_bnad018-B151","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1530\/ERC-10-0235","article-title":"Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma","volume":"18","author":"Tone","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2024042614111135000_bnad018-B152","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.18632\/oncotarget.21378","article-title":"Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling","volume":"9","author":"Singhal","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2024042614111135000_bnad018-B153","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","article-title":"Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions","volume":"33","author":"Wu","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"2024042614111135000_bnad018-B154","doi-asserted-by":"publisher","first-page":"T35","DOI":"10.1530\/JME-19-0274","article-title":"90 years of progesterone: steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide","volume":"65","author":"Dwyer","year":"2020","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"2024042614111135000_bnad018-B155","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1677\/jme.0.0240165","article-title":"Association of the Ku autoantigen\/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding domain of progesterone receptors","volume":"24","author":"Sartorius","year":"2000","journal-title":"J Mol Endocrinol"},{"issue":"7","key":"2024042614111135000_bnad018-B156","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.steroids.2008.12.001","article-title":"Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation","volume":"74","author":"Dressing","year":"2009","journal-title":"Steroids"},{"issue":"13","key":"2024042614111135000_bnad018-B157","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/bph.15746","article-title":"Structural and molecular determinants of mineralocorticoid receptor signalling","volume":"179","author":"Grossmann","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2024042614111135000_bnad018-B158","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1210\/en.2016-1778","article-title":"Family matters: collaboration and conflict among the steroid receptors raises a need for group therapy","volume":"157","author":"Sikora","year":"2016","journal-title":"Endocrinology"},{"issue":"10","key":"2024042614111135000_bnad018-B159","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/09513590.2010.538100","article-title":"Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species","volume":"27","author":"Nguyen","year":"2011","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"2024042614111135000_bnad018-B160","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2016.04.022","article-title":"Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: an opportunity for chemoprevention","volume":"143","author":"Rodriguez","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2024042614111135000_bnad018-B161","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.celrep.2017.02.049","article-title":"Progesterone prevents high-grade serous ovarian cancer by inducing necroptosis of p53-defective fallopian tube epithelial cells","volume":"18","author":"Wu","year":"2017","journal-title":"Cell Rep"},{"issue":"4","key":"2024042614111135000_bnad018-B162","doi-asserted-by":"publisher","first-page":"106523","DOI":"10.1016\/j.isci.2023.106523","article-title":"Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine","volume":"26","author":"Wu","year":"2023","journal-title":"iScience"},{"issue":"4","key":"2024042614111135000_bnad018-B163","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.molcel.2006.01.014","article-title":"Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression","volume":"21","author":"Cvoro","year":"2006","journal-title":"Mol Cell"},{"issue":"4","key":"2024042614111135000_bnad018-B164","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/onc.2013.579","article-title":"Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes","volume":"34","author":"Daniel","year":"2015","journal-title":"Oncogene"},{"issue":"9","key":"2024042614111135000_bnad018-B165","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1091\/mbc.E12-11-0807","article-title":"Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes","volume":"24","author":"Bellance","year":"2013","journal-title":"Mol Biol Cell"},{"issue":"2","key":"2024042614111135000_bnad018-B166","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1530\/JOE-11-0310","article-title":"Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor-1","volume":"214","author":"Diaz","year":"2012","journal-title":"J Endocrinol"},{"issue":"2","key":"2024042614111135000_bnad018-B167","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/ERC-09-0258","article-title":"Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase","volume":"17","author":"Fu","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2024042614111135000_bnad018-B168","doi-asserted-by":"publisher","first-page":"105492","DOI":"10.1016\/j.jsbmb.2019.105492","article-title":"Effect of progesterone and first evidence about allopregnanolone action on the progression of epithelial human ovarian cancer cell lines","volume":"196","author":"Pelegrina","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2024042614111135000_bnad018-B169","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ebiom.2019.08.035","article-title":"Molecular mechanisms underlying mifepristone","volume":"47","author":"Ponikwicka-Tyszko","year":"2019","journal-title":"EBioMedicine"},{"issue":"10","key":"2024042614111135000_bnad018-B170","doi-asserted-by":"publisher","first-page":"e86829","DOI":"10.1172\/jci.insight.86829","article-title":"Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition","volume":"1","author":"Iwanicki","year":"2016","journal-title":"JCI Insight"},{"key":"2024042614111135000_bnad018-B171","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jsbmb.2018.08.011","article-title":"Progesterone up-regulates p27 through an increased binding of the progesterone receptor-A-p53 protein complex onto the non-canonical p53 binding motif in HUVEC","volume":"185","author":"Hsu","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"2024042614111135000_bnad018-B172","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1210\/en.2014-1629","article-title":"Progesterone receptor-NF\u03baB complex formation is required for progesterone-induced NF\u03baB nuclear translocation and binding onto the p53 promoter","volume":"156","author":"Hsu","year":"2015","journal-title":"Endocrinology"},{"issue":"652","key":"2024042614111135000_bnad018-B173","doi-asserted-by":"publisher","first-page":"eaaz9646","DOI":"10.1126\/scisignal.aaz9646","article-title":"Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms","volume":"13","author":"Wetendorf","year":"2020","journal-title":"Sci Signal"},{"issue":"13","key":"2024042614111135000_bnad018-B174","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.3390\/ijms21134806","article-title":"Modelling epithelial ovarian cancer in mice: classical and emerging approaches","volume":"21","author":"Zakarya","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2024042614111135000_bnad018-B175","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1073\/pnas.1117135109","article-title":"High-grade serous ovarian cancer arises from fallopian tube in a mouse model","volume":"109","author":"Kim","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"2024042614111135000_bnad018-B176","doi-asserted-by":"publisher","first-page":"31993","DOI":"10.1073\/pnas.2013595117","article-title":"Targeting progesterone signaling prevents metastatic ovarian cancer","volume":"117","author":"Kim","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2024042614111135000_bnad018-B177","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","article-title":"Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers","volume":"21","author":"Burleson","year":"2004","journal-title":"Clin Exp Metastasis"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnad018\/50918870\/bnad018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/44\/6\/1029\/57339647\/bnad018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/44\/6\/1029\/57339647\/bnad018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T14:11:53Z","timestamp":1714140713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/44\/6\/1029\/7188165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":177,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnad018","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,1]]}}}